1. Home
  2. UFCS vs EVO Comparison

UFCS vs EVO Comparison

Compare UFCS & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Fire Group Inc.

UFCS

United Fire Group Inc.

HOLD

Current Price

$48.48

Market Cap

936.4M

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.69

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UFCS
EVO
Founded
1946
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
936.4M
934.1M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
UFCS
EVO
Price
$48.48
$2.69
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$40.50
$7.00
AVG Volume (30 Days)
97.5K
94.1K
Earning Date
05-05-2026
04-08-2026
Dividend Yield
2.01%
N/A
EPS Growth
87.45
N/A
EPS
1.15
N/A
Revenue
$1,386,412,000.00
N/A
Revenue This Year
$11.80
$1.37
Revenue Next Year
$8.77
$10.05
P/E Ratio
$42.65
N/A
Revenue Growth
10.62
N/A
52 Week Low
$25.81
$2.31
52 Week High
$49.87
$4.80

Technical Indicators

Market Signals
Indicator
UFCS
EVO
Relative Strength Index (RSI) 74.64 36.25
Support Level $34.84 $2.32
Resistance Level N/A $3.78
Average True Range (ATR) 1.59 0.09
MACD 0.69 -0.06
Stochastic Oscillator 85.81 6.44

Price Performance

Historical Comparison
UFCS
EVO

About UFCS United Fire Group Inc.

United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: